Difference between revisions of "Eluvixtamab (AMG-330)"
Jump to navigation
Jump to search
m |
m |
||
| Line 4: | Line 4: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| + | [[Category:Immunotherapy]] | ||
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
| + | [[Category:T-cell activators]] | ||
[[Category:BiTE antibodies]] | [[Category:BiTE antibodies]] | ||
[[Category:Anti-CD33 antibodies]] | [[Category:Anti-CD33 antibodies]] | ||
Revision as of 23:11, 17 December 2014
Mechanism of action
Bispecific T-cell engager (BiTE) antibody that engages CD33 and CD3